Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Colobreathe

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

Novartis day

Novartis defends Zolgensma as FDA investigates ‘data manipulation’

Gene therapy will remain on the market

Novartis day

Blow for Entresto in latest heart failure trial

Aim of being first in HFpEF in serious doubt

- PMLiVE

AZ and Novartis ‘most exposed’ to Senate pricing proposals

Most expensive therapies will be penalised

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

- PMLiVE

NICE unveils long-awaited review of methodologies

Use of quality of life measures to be reviewed

- PMLiVE

Vertex files cystic fibrosis triple therapy with FDA

A landmark for company - but pricing controversy awaits

Novartis day

Novartis raises 2019 guidance as new products gather speed

Cosentyx leads the way with 25% growth

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

- PMLiVE

FDA starts speedy review of Novartis’ sickle cell antibody

Among several $1bn+ late-stage drugs in company's pipeline

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

- PMLiVE

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Latest BACE inhibitor to run into trouble

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links